Trial Profile

A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients with Newly Diagnosed Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isatuximab (Primary) ; Isatuximab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms GMMG-HD8/DSMM

07 Mar 2025 Status changed from recruiting to active, no longer recruiting.
08 May 2024 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.
28 Feb 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com